ArticleJournal of medicinal chemistry2025
Recognition of the CREB-Binding Protein/Mixed Lineage Leukemia Interface by Sulfonyl-γ-AApeptides: Beyond Mimicry of Mixed Lineage Leukemia.
Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- De Novo Design of Multivalent α/β-Peptides Mimicking Transcription Factors Targeting the CBP KIX Domain.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Recent Exploration of Right-Handed D-Sulfonyl-γ-AApeptides as Potential Tools Toward α-Helical Mimicry.ChemPlusChem · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The kinase-inducible (KIX) domain, a structured region within the transcriptional coactivators CREB-binding protein (CBP) and p300, serves as a docking site for multiple transcription factors, including the mixed lineage leukemia (MLL) protein. The MLL-KIX protein-protein interaction (PPI) has been implicated in various diseases, such as leukemia, cancer, and neurodegenerative disorders, including Alzheimer's disease. In this study, we developed a series of MLL-mimicking peptidomimetic foldamers based on a sulfonyl-γ-AApeptide backbone. These helical foldamers successfully mimic the folded transactivation domain (TAD) of MLL and bind the KIX domain with a high affinity. Consistent with the notion that MLL-KIX interaction can allosterically enhance CREB signaling, we found that the sulfonyl-γ-AApeptides strongly stimulate CREB-dependent gene expression. Moreover, they exhibit no significant cytotoxicity under the tested conditions, demonstrating both binding specificity and therapeutic potential for targeting CREB-related pathways in neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.